Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria

Trial Profile

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2018

At a glance

  • Drugs UB 221 (Primary)
  • Indications Urticaria
  • Focus Adverse reactions
  • Sponsors United BioPharma
  • Most Recent Events

    • 23 Aug 2018 New trial record
    • 12 Jul 2018 According to a United BioPharma media release, the company has submitted an application for the first phase clinical trial of the new anti-IgE antibody UB-221 to the Taiwan Food and Drug Administration (TFDA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top